Melanoma combo study halted before full results

NCT ID NCT01604889

Terminated Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

First seen Apr 24, 2026 · Last updated Apr 30, 2026 · Updated 1 time

Summary

This study tested whether adding the drug epacadostat to the approved immunotherapy ipilimumab could help people with advanced melanoma that cannot be removed by surgery or has spread. The study planned to enroll 50 adults aged 18 and older. However, the study was stopped early for business reasons, so only the first phase (checking safety) was completed. No conclusions can be drawn about how well the combination works.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Study site

Los Angeles, California, United States
Study site

Miami, Florida, United States
Study site

Tampa, Florida, United States
Study site

Chicago, Illinois, United States
Study site

Durham, North Carolina, United States
Study site

Philadelphia, Pennsylvania, United States
Study site

Pittsburgh, Pennsylvania, United States

Conditions

Explore the condition pages connected to this study.

MELANOMA